专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07132452B2 Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection 失效
标题翻译：具有减轻疱疹病毒感染引起的疼痛/炎症作用的局部制剂
公开(公告)号：US07132452B2
公开(公告)日：2006-11-07
申请号：US10383525
申请日：2003-03-10
申请人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yen-Ling Yi , Wei-Liang Lin
发明人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yen-Ling Yi , Wei-Liang Lin
IPC分类号： A61K31/19 , A61K31/60 , A61K9/14
CPC分类号： A61K9/0014 , A61K31/19 , A61K31/195 , A61K31/196 , A61K31/381 , A61K31/40 , A61K31/405 , A61K31/415 , A61K31/54 , Y10S514/944
摘要： The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.
摘要翻译：本发明提供含有NSAID，特别是双氯芬酸的局部制剂。局部制剂对于缓解由疱疹病毒，特别是单纯疱疹病毒（HSV）和水痘带状疱疹病毒（VZV）引起的感染相关的疼痛/炎症特别有用。双氯芬酸用另一种非甾体抗炎药（NSAID）替代，可以达到类似的缓解，其中包括但不限于依托度酸，酮咯酸，溴芬酸，二氟尼柳，布洛芬，非诺洛芬，酮洛芬，萘普生，脱芬，甲氯芬那酸，甲芬那酸，吡罗昔康，美洛昔康，吲哚美辛，舒林酸，保泰松，氧保生素和托美丁。局部制剂的特征还在于其快速释放与由疱疹病毒引起的感染相关的疼痛和/或炎症，即在将局部制剂施用于患者皮肤后不超过七（7）天内完全缓解。

2. 发明授权

US07166641B2 Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same 有权
标题翻译：含有局部麻醉剂和抗炎活性的药学上可接受的盐及其制备方法
公开(公告)号：US07166641B2
公开(公告)日：2007-01-23
申请号：US10262098
申请日：2002-10-02
申请人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yen-Ling Yi
发明人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yen-Ling Yi
IPC分类号： A61K31/195 , A61K31/19
CPC分类号： C07D487/04 , A61K31/167 , A61K31/196 , A61K45/06 , C07C229/42 , C07C237/04 , Y10S514/97 , A61K2300/00
摘要： The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug (“NSAID”). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses. These pharmaceutically acceptable salts are suitable for use in topical treatment or parenteral injection to treat patients with localized pain, including muscle pain, joint pain, pain associated with herpes infection, and wound pain (such as surgical wound, burn wound etc.).
摘要翻译：本发明提供具有局部麻醉和抗炎活性的药学上可接受的盐。优选的药学上可接受的盐是利多卡因的双氯芬酸盐。双氯芬酸是非甾体抗炎药（“NSAID”）。利多卡因是局麻药。其他NSAID（NSAID的水杨酸衍生物除外）可用于替代双氯芬酸和/或其他局部麻醉剂，可用于替代利多卡因。药学上可接受的盐是结晶化合物，它们与单独使用的NSAID或单独的局部麻醉剂明显不同，如差示扫描量热法（DSC），热重分析（TGA），高效液相色谱（HPLC）和傅里叶变换红外光谱（FTIR）分析。这些药学上可接受的盐适用于局部治疗或肠胃外注射以治疗局部疼痛的患者，包括肌肉疼痛，关节疼痛，与疱疹感染相关的疼痛和伤口疼痛（例如手术伤口，烧伤伤口等）。

3. 发明授权

US07361683B2 Paclitaxel aqueous injection solution and methods for preparing the same 失效
标题翻译：紫杉醇注射液及其制备方法
公开(公告)号：US07361683B2
公开(公告)日：2008-04-22
申请号：US10995262
申请日：2004-11-24
申请人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yuan-Ken Lin
发明人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yuan-Ken Lin
IPC分类号： A61K31/335
CPC分类号： A61K31/337 , A61K9/0019 , A61K47/08 , A61K47/44
摘要： The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an effective amount of paclitaxel, which is dissolved in polyoxyethylated castor oil, alcohol, and an injectable aqueous solution. A sufficient amount of CO2 is added to stabilize paclitaxel in the injectable pharmaceutical composition to make the injectable pharmaceutical composition to a pH about 5.0.
摘要翻译：本发明提供含有紫杉醇作为活性成分的抗癌剂的可注射药物组合物。可注射药物组合物包含有效量的紫杉醇，其溶解在聚氧乙烯化蓖麻油，醇和可注射水溶液中。加入足够量的CO 2以稳定可注射药物组合物中的紫杉醇，使可注射药物组合物的pH约为5.0。

4. 发明申请

US20060111432A1 Paclitaxel aqueous injection solution and methods for preparing the same 失效
标题翻译：紫杉醇注射液及其制备方法
公开(公告)号：US20060111432A1
公开(公告)日：2006-05-25
申请号：US10995262
申请日：2004-11-24
申请人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yuan-Ken Lin
发明人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Chiung-Ju Tsai , Yuan-Ken Lin
IPC分类号： A61K31/337 , A61K33/00
CPC分类号： A61K31/337 , A61K9/0019 , A61K47/08 , A61K47/44
摘要： The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an effective amount of paclitaxel, which is dissolved in polyoxyethylated castor oil, alcohol, and an injectable aqueous solution. A sufficient amount of CO2 is added to stabilize paclitaxel in the injectable pharmaceutical composition to make the injectable pharmaceutical composition to a pH about 5.0.
摘要翻译：本发明提供含有紫杉醇作为活性成分的抗癌剂的可注射药物组合物。可注射药物组合物包含有效量的紫杉醇，其溶解在聚氧乙烯化蓖麻油，醇和可注射水溶液中。加入足够量的CO 2以稳定可注射药物组合物中的紫杉醇，使可注射药物组合物的pH约为5.0。

5. 发明申请

US20070148240A1 Oral formulation containing itraconazole and methods for manufacturing and using the same 审中-公开
标题翻译：含有伊曲康唑的口服制剂及其制造和使用方法
公开(公告)号：US20070148240A1
公开(公告)日：2007-06-28
申请号：US11315124
申请日：2005-12-23
申请人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-Chiung Chen , Bin-Ken Chen , Han-Chiang Kuo
IPC分类号： A61K9/24 , A61K31/496
CPC分类号： A61K9/209 , A61K9/2054 , A61K31/496
摘要： The present invention provides oral pharmaceutical formulation for azole antimicrobial drugs such as itraconazole, saperconazole, ketoconazole, and fluconazole. The oral pharmaceutical formulation contains a core and a drug coating layer. The drug coating layer contains the azole antimicrobial drug and a binder, but not containing an emulsion (such as polyoxypropylene-polyoxyethylene block copolymers, polyoxyethylene-sorbitan-fatty acid esters, sodium lauryl sulfate, or vitamin E polyethylene glycol succinate) and/or an absorbent aid (such as DL-malic acid, citric acid, ascorbic acid, and alginic acid). The oral pharmaceutical formulation can optionally contain a protective layer, such as polyethylene glycol 20,000. The present invention also provides a method for preparing and using the formulation.
摘要翻译：本发明提供了唑吡唑，沙康唑，酮康唑，氟康唑等唑类抗菌药物的口服药物制剂。口服药物制剂含有核心和药物包衣层。药物包衣层包含唑类抗微生物药物和粘合剂，但不含乳液（例如聚氧丙烯 - 聚氧乙烯嵌段共聚物，聚氧乙烯脱水山梨醇脂肪酸酯，十二烷基硫酸钠或维生素E聚乙二醇琥珀酸酯）和/或吸收助剂（如DL-苹果酸，柠檬酸，抗坏血酸和海藻酸）。口服药物制剂可任选地含有保护层，例如聚乙二醇20,000。本发明还提供了制备和使用制剂的方法。

6. 发明授权

US06902746B2 Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same 失效
标题翻译：含有非甾体抗炎药的口服药物组合物及其制备方法
公开(公告)号：US06902746B2
公开(公告)日：2005-06-07
申请号：US10187899
申请日：2002-07-03
申请人： Fang-Yu Lee , Shan-Chiung Chen , Ping-Kuen Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-Chiung Chen , Ping-Kuen Chen , Han-Chiang Kuo
IPC分类号： A61K9/32 , A61K9/50 , A61K31/205 , A61K31/407 , A61K47/04 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61P29/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/48
CPC分类号： A61K31/205 , A61K9/5078
摘要： The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.
摘要翻译：本发明提供了用于乙酸类非甾体抗炎药（NSAID）的口服药物组合物，特别是酮咯酸。药物组合物含有核心，药物层（其包含药物，粘合剂和崩解剂），保护层和肠溶衣层。口服药物组合物特别适用于治疗中度至急性疼痛的患者。本发明还提供了制备药物组合物的方法和使用该药物组合物的方法。

7. 发明授权

US06168806A Orally administrable nifedipine pellet and process for the preparation thereof 失效
标题翻译：口服给药的硝苯地平丸剂及其制备方法
公开(公告)号：US06168806A
公开(公告)日：2001-01-02
申请号：US09263693
申请日：1999-03-05
申请人： Fang-Yu Lee , Shan-Chiung Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-Chiung Chen , Han-Chiang Kuo
IPC分类号： A61K916
CPC分类号： A61K31/4422 , A61K9/1676 , A61K9/5078 , Y10S514/962
摘要： The present invention relates to a fast-release as well as a prolonged release type of nifedipine pellets and the process for the preparation thereof. The fast-release type of nifedipine pellets comprises a particulate core which is covered by a nifedipine coating layer. The particulate core comprises water-soluble or water-insoluble excipient(s) and a pharmacologically acceptable carrier. The nifedipine coating layer comprises an effective amount of nifedipine dissolved in organic solvent(s). This nifedipine coating layer can further be mixed with a suspension which comprises an adhesive, an emulsifier, and a dispersant. The preferred composition of the fast-release type of nifedipine includes 20-70% of the particulate core, 3-15% of nifedipine, 1-20% of emulsifier, 1-20% of adhesive, and 1-30% of dispersant. The prolonged-release type of nifedipine pellets comprises, in addition to the particulate core and the nifedipine coating layer, a surface coating layer which is made of at lease one consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose and ethylcellulose. This surface coating layer further comprises a plasticizer which is selected from the group consisting of triethylcitrate, triacetin, and diethyl phthalate.
摘要翻译：本发明涉及快速释放和延缓释放型硝苯地平丸剂及其制备方法。硝苯地平丸剂的快速释放类型包括被硝苯地平涂层覆盖的颗粒芯。颗粒核心包括水溶性或水不溶性赋形剂和药理学上可接受的载体。硝苯地平涂层包含溶解在有机溶剂中的有效量的硝苯地平。该硝苯地平涂层可以进一步与包含粘合剂，乳化剂和分散剂的悬浮液混合。快速释放型硝苯地平的优选组成包括20-70％的颗粒核，3-15％的硝苯地平，1-20％的乳化剂，1-20％的粘合剂和1-30％的分散剂。硝苯地平丸剂的延长释放型除了颗粒状核心和硝苯地平涂层外还包含由至少由羟丙基纤维素，羟丙基甲基纤维素和乙基纤维素组成的表面涂层。该表面涂层还包含选自柠檬酸三乙酯，三醋精和邻苯二甲酸二乙酯的增塑剂。

8. 发明授权

US06228400B1 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same 失效
标题翻译：口服给药苯并咪唑衍生物的药物制剂及其制备方法
公开(公告)号：US06228400B1
公开(公告)日：2001-05-08
申请号：US09488406
申请日：2000-01-19
申请人： Fang-Yu Lee , Shan-chiung Chen , Han-Chiang Kuo
发明人： Fang-Yu Lee , Shan-chiung Chen , Han-Chiang Kuo
IPC分类号： A61K914
CPC分类号： A61K9/5078 , A61K31/4439
摘要： The present invention provides pharmaceutical formulations which contain (a) an inert core of sugar, sugar and starch, or microcrystalline cellulose, (b) a drug emulsion layer which is made from mixing a free base of benzimidazole derivative (such as omeprazole or lansoprazole) with a nonionic surfactant and water, (c) a protective coating which is made of a film-forming compound, and optionally a plasticizer or excipient, and (d) an enteric coating which is made of a pharmaceutically acceptable polymer and a plasticizer. Optionally, a basic amino acid can be added to the drug emulsion layer or the protective coating. The present invention also provides the method for making the pharmaceutical formulations.
摘要翻译：本发明提供了含有（a）糖，糖和淀粉或微晶纤维素的惰性核心的药物制剂，（b）由苯并咪唑衍生物（如奥美拉唑或兰索拉唑）的游离碱混合制成的药物乳剂层，非离子表面活性剂和水，（c）由成膜化合物和任选的增塑剂或赋形剂制成的保护涂层，和（d）由药学上可接受的聚合物和增塑剂制成的肠溶衣。任选地，可将碱性氨基酸加入到药物乳剂层或保护性涂层中。本发明还提供了制备药物制剂的方法。

9. 发明授权

US07202062B2 Strains of Saccharaothrix, process for producing pravastain using the strains and isolation process of (HMG)-CoA reductase 失效
标题翻译： Saccharaothrix菌株，使用（HMG）-CoA还原酶的菌株和分离过程生产普伐他汀的方法
公开(公告)号：US07202062B2
公开(公告)日：2007-04-10
申请号：US10727643
申请日：2003-12-03
申请人： Fang-Yu Lee , Ming-Liang Lee , Anderson C. Hong , Schung-Ching Chiu
发明人： Fang-Yu Lee , Ming-Liang Lee , Anderson C. Hong , Schung-Ching Chiu
IPC分类号： C12P17/06 , C12N1/20
CPC分类号： C12R1/01 , C12P7/62 , C12P17/06
摘要： The present invention provides two new microorganism strains of Saccharothrix, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.
摘要翻译：本发明提供两种新的Saccharothrix微生物菌株，称为YS-44442和YS-45494，使用菌株生产普伐他汀的方法，以及用于分离（HMG）-CoA还原酶抑制剂的改进方法。

10. 发明授权

US07176230B2 Synthesis of indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole (YC-1) as anti-platelet agents 有权
标题翻译： 1-苄基-3-（5'-羟甲基-2'-呋喃基）吲唑（YC-1）作为抗血小板剂的吲哚类似物的合成
公开(公告)号：US07176230B2
公开(公告)日：2007-02-13
申请号：US11274436
申请日：2005-11-15
申请人： Sheng-Chu Kuo , Fang-Yu Lee , Tsang-Miao Huang , Che-Ming Teng , On Lee , Chin-Yi Wu , Chrong-Shiong Hwang , Chi-Ying Hung
发明人： Sheng-Chu Kuo , Fang-Yu Lee , Tsang-Miao Huang , Che-Ming Teng , On Lee , Chin-Yi Wu , Chrong-Shiong Hwang , Chi-Ying Hung
IPC分类号： A61K31/405 , C07D209/04
CPC分类号： C07D209/12 , C07D405/04 , C07D409/04
摘要： The present invention synthesizes a series of novel indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (YC-1), and their anti-platelet activity.
摘要翻译：本发明合成了一系列1-苄基-3-（5'-羟甲基-2'-呋喃基）吲唑（YC-1）的新吲哚类似物及其抗血小板活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式